-DOCSTART- -X- O
mRNA -X- _ O
technologies -X- _ O
have -X- _ O
the -X- _ O
potential -X- _ O
to -X- _ O
transform -X- _ O
areas -X- _ O
of -X- _ O
medicine -X- _ O
, -X- _ O
including -X- _ O
the -X- _ O
prophylaxis -X- _ B-Patient
of -X- _ I-Patient
infectious -X- _ I-Patient
diseases. -X- _ I-Patient
The -X- _ O
advantages -X- _ O
for -X- _ O
vaccines -X- _ O
range -X- _ O
from -X- _ O
the -X- _ O
acceleration -X- _ O
of -X- _ O
immunogen -X- _ O
discovery -X- _ O
to -X- _ O
rapid -X- _ O
response -X- _ O
and -X- _ O
multiple -X- _ O
disease -X- _ O
target -X- _ O
manufacturing. -X- _ O
A -X- _ O
greater -X- _ O
understanding -X- _ O
of -X- _ O
quality -X- _ O
attributes -X- _ O
that -X- _ O
dictate -X- _ O
translation -X- _ O
efficiency -X- _ O
, -X- _ O
as -X- _ O
well -X- _ O
as -X- _ O
a -X- _ O
comprehensive -X- _ O
appreciation -X- _ O
of -X- _ O
the -X- _ O
importance -X- _ O
of -X- _ O
mRNA -X- _ O
delivery -X- _ O
, -X- _ O
are -X- _ O
influencing -X- _ O
a -X- _ O
new -X- _ O
era -X- _ O
of -X- _ O
investment -X- _ O
in -X- _ O
development -X- _ O
activities. -X- _ O
The -X- _ O
application -X- _ O
of -X- _ O
translational -X- _ O
sciences -X- _ O
and -X- _ O
growing -X- _ O
early-phase -X- _ O
clinical -X- _ O
experience -X- _ O
continue -X- _ O
to -X- _ O
inform -X- _ O
candidate -X- _ O
vaccine -X- _ O
selection. -X- _ O
Here -X- _ O
we -X- _ O
review -X- _ O
the -X- _ O
state -X- _ O
of -X- _ O
the -X- _ O
art -X- _ O
for -X- _ O
the -X- _ O
prevention -X- _ B-Outcome
of -X- _ I-Outcome
infectious -X- _ I-Outcome
diseases -X- _ I-Outcome
by -X- _ O
using -X- _ O
mRNA -X- _ B-Intervention
and -X- _ I-Intervention
pertinent -X- _ I-Intervention
topics -X- _ I-Intervention
to -X- _ I-Intervention
the -X- _ I-Intervention
biotechnology -X- _ I-Intervention
and -X- _ I-Intervention
pharmaceutical -X- _ I-Intervention
industries -X- _ I-Intervention
. -X- _ O

